CTRI/2020/02/023447尚未招募2 期
Sequential Abiraterone following Docetaxel Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer - SAD HORSE
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Participants must be hormone sensitive prostate cancer for a histologically confirmed adenocarcinoma of prostate.
- •2. ECOG performance status <=2.
- •3. Participants must have normal organ and marrow function.
排除标准
- •1. Participants who are receiving any other investigational agents.
- •2. Participants who are designated as unfit for receiving Abiraterone based chemotherapy.
研究者
相似试验
招募中
2 期
pfront therapy in high risk metastatic prostate cancermetastatic hormone naive prostate cancerprostate cancer, hormone naive, metastaticJPRN-jRCTs021180021arita Shintaro100
招募中
3 期
The study of compairing benefit of Abiraterone low versus full dose with Docetaxel in Prostate CancerCTRI/2023/03/050180Tata Memorial Hospital
进行中（未招募）
2 期
Docetaxel plus Ramucirumab immediately after treatment with ICInon-small cell lung cancer, adenocarcinoma, squamous cell carcinomanon-small cell lung cancerJPRN-jRCT1051190091Akamatsu Hiroaki35
已完成
2 期
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate CancerProstate CancerNCT01393730Mary-Ellen Taplin, MD40
招募中
2 期
The effect of addition of low dose abiraterone to the ADT+RT in local recurrent prostate cancersProstate cancer.Malignant neoplasm of prostateIRCT20120618010057N2Shahid Beheshti University of Medical Sciences64